87% of Drug Makers Say 2018 Pricing Reform Hit Their R&D, Businesses: MHLW Survey

Nearly 87% of pharmaceutical companies granted the so-called price maintenance premium (PMP) for their products said that Japan’s pricing overhaul in April 2018 affected their new drug R&D and businesses, with many hinting at ongoing and future changes in their...read more